BlackRock
NXTC icon

BlackRock’s NextCure NXTC Stock Holding History

BlackRock’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.8K Buy
37,348
+9,555
+34% +$70.6K ﹤0.01% 5136
2026
Q1 		$297K Hold
27,793
– – ﹤0.01% 4657
2025
Q4 		$394K Sell
27,793
-3,293
-11% -$34.1K ﹤0.01% 4544
2025
Q3 		$182K Sell
31,086
-249
-0.8% -$1.3K ﹤0.01% 4698
2025
Q2 		$173K Sell
31,335
-15,056
-32% -$80.8K ﹤0.01% 4705
2025
Q1 		$267K Sell
46,391
-14,241
-23% -$126K ﹤0.01% 4547
2024
Q4 		$561K Sell
60,632
-188
-0.3% -$2.77K ﹤0.01% 4380
2024
Q3 		$1,000K Sell
60,820
-2,612
-4% -$48.1K ﹤0.01% 4175
2024
Q2 		$1.21M Sell
63,432
-13
-0% -$253 ﹤0.01% 4128
2024
Q1 		$1.7M Sell
63,445
-10,730
-14% -$185K ﹤0.01% 4057
2023
Q4 		$1.01M Sell
74,175
-667
-0.9% -$9.67K ﹤0.01% 4248
2023
Q3 		$1.16M Sell
74,842
-2,268
-3% -$43.3K ﹤0.01% 4200
2023
Q2 		$1.67M Buy
77,110
+75
+0.1% +$1.48K ﹤0.01% 4134
2023
Q1 		$1.37M Sell
77,035
-10,196
-12% -$196K ﹤0.01% 4220
2022
Q4 		$1.48M Sell
87,231
-16,675
-16% -$384K ﹤0.01% 4260
2022
Q3 		$3.43M Sell
103,906
-1,472
-1% -$75K ﹤0.01% 3924
2022
Q2 		$5.94M Sell
105,378
-132
-0.1% -$6.89K ﹤0.01% 3745
2022
Q1 		$6.15M Buy
105,510
+1,999
+2% +$125K ﹤0.01% 3843
2021
Q4 		$7.45M Buy
103,511
+1,011
+1% +$84.6K ﹤0.01% 3823
2021
Q3 		$8.29M Buy
102,500
+2,109
+2% +$185K ﹤0.01% 3757
2021
Q2 		$9.68M Sell
100,391
-79,456
-44% -$8.13M ﹤0.01% 3654
2021
Q1 		$21.6M Buy
179,847
+53,627
+42% +$7.77M ﹤0.01% 3147
2020
Q4 		$16.5M Buy
126,220
+23,821
+23% +$3.08M ﹤0.01% 3111
2020
Q3 		$10.8M Buy
102,399
+11,912
+13% +$1.46M ﹤0.01% 3183
2020
Q2 		$23.3M Sell
90,487
-2,180
-2% -$830K ﹤0.01% 2721
2020
Q1 		$41.2M Buy
92,667
+816
+0.9% +$436K ﹤0.01% 2178
2019
Q4 		$62.1M Buy
91,851
+71,879
+360% +$36.1M ﹤0.01% 2228
2019
Q3 		$7.39M Buy
19,972
+8,664
+77% +$2.82M ﹤0.01% 3358
2019
Q2 		$2.03M Buy
+11,308
New +$2.35M ﹤0.01% 3780

Other funds holding NXTC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock's NXTC Position: Q2 2026 in Review

BlackRock increased its NextCure (NXTC) stake by 34% in Q2 2026, buying an estimated $70.6K and bringing the position to 37,348 shares worth $59.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5136.

BlackRock first reported a position in NXTC in Q2 2019 and has held it in 29 quarters since. The position peaked at $62.1M in Q4 2019. 17 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • BlackRock held 37,348 shares of NextCure worth $59.8K as of Q2 2026.
  • BlackRock bought 9,555 NextCure shares in Q2 2026, an estimated $70.6K.
  • NextCure made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5136 holding.
  • BlackRock first reported a position in NextCure in Q2 2019 and has held it in 29 quarters since.
  • BlackRock's NextCure position peaked at $62.1M in Q4 2019.
  • 17 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.